Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand

International Journal of Dermatology

Volumn 50, Issue 4, 2011, Pages 428-435

  Aunhachoke, Kobkul ^a   Bussaratid, Valai ^b   Chirachanakul, Pornchai ^c   Chua Intra, Boosbun ^c   Dhitavat, Jittima ^b   Jaisathaporn, Kanokporn ^d   Kaewkungwal, Jaranit ^b   Kampirapap, Kowit ^e   Khuhaprema, Thiravud ^d   Pairayayutakul, Kulprapat ^f   Pitisuttithum, Punnee ^b   Sindhvananda, Jirot ^e   Thaipisuttikul, Yupin ^g  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

^d NATIONAL CANCER INSTITUTE   (Thailand)

^e Institute of Dermatology Thailand   (Thailand)

^f Raj Pracha Samasai Inst   (Thailand)

^g RAJAVITHI HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; DAILY LIFE ACTIVITY; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HERPES ZOSTER OTICUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; QUALITY OF LIFE; RASH; THAILAND;

ADULT; AGED; AMBULATORY CARE; COHORT STUDIES; FEMALE; HEALTH EXPENDITURES; HERPES ZOSTER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; NIACINAMIDE; PIPERAZINES; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SICK LEAVE; SOCIOECONOMIC FACTORS; THAILAND;

EID: 79952750265     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04715.x     Document Type: Article

References (21)

1. Bureau of Epidemiology, Thailand.. [Accessed January 1st, 2010].
2. Johnson RW, Dworkin RH. Treatment of herpes zoster and post-herpetic neuralgia. BMJ 2003; 326: 748-750.
3. Opstelten W, Zaal MJW. Managing ophthalmic herpes zoster in primary care. BMJ 2005; 331: 147-151.
4. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341-1349.
5. Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella vaccination-associated decrease in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191: 2002-2007.
6. Oxman MN, Levin MJ; Shingles Prevention Study Group. Vaccination against herpes zoster and post-herpetic neuralgia. J Infect Dis 2008; 2: 228-236.
7. Chaves SS, Santibanez TA, Gargiullo P, Guris D. Chicken pox exposure and herpes zoster disease incidence in older adults in the US. Public Health Rep 2007; 122: 155-159.
8. Gnann JW Jr, Whitley RJ. Herpes zoster. N Engl J Med 2002; 347: 340-346.
9. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166: 1153-1156.
10. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and post-herpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5: 344-356.
11. Jackson JL, Gibbons R, Meyer G. The effect of treating herpes zoster with oral acyclovir in preventing post-herpetic neuralgia: a meta-analysis. Arch Intern Med 1997; 157: 909-912.
12. Wood MJ, Kay R, Dworkin RH. Oral acyclovir treatment accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341-347.
13. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and post-herpetic neuralgia. Ann Intern Med 1995; 123: 89-96.
14. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing post-herpetic neuralgia. Cochrane Database Syst Rev 2009; 15: CD006866.
15. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137: 38-47.
16. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995; 8: 52-53.
17. Haythornthwaite JA, Clark MR, Pappagallo M, Raja SN. Pain coping strategies play a role in the persistence of pain in post-herpetic neuralgia. Pain 2003; 106: 453-460.
18. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007; 68: 1178-1182.
19. Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: health care resource utilization and costs in a group of US health plans. Pharmacoeconomics 2007; 25: 155-169.
20. Stein AN, Britt H, Christopher H, et al. Herpes zoster burden of illness and health care resource utilization in the Australian population aged 50 years and older. Vaccine 2009; 27: 520-529.
21. Nowgesic E, Skowronski D, King A, Hockin J. Direct cost attributed to chicken pox and herpes zoster in British Columbia 1992-1996. Can Commun Dis Rep 1999; 25: 100-104.